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Autoimmune hepatitis (AIH) is a complex liver disease of unknown cause which results in immune-mediated liver injury with varied clinical presentations. Seronegative 
AIH follows a similar course to autoantibody-positive disease and 
diagnosis might be challenging. Delay in appropriate treatment 
might lead to the progression of liver disease and liver failure. 
AIH occurs more commonly in females between the ages of 40 
and 50 years, though it has been reported in children and adults 
of all ages. Diagnostic criteria used for conventional AIH might 
not be applicable to cases with seronegative AIH [1]. There is no 
diagnostic scoring system specially designed for children.
CASE REPORT
An 11-year-old boy was admitted in our hospital with a history 
of yellowish discoloration of eyes, skin, and high-colored urine 
for 2 months. Anorexia was also reported for 2 months. He had 
fever for 1½ months and itching for 15 days. He was passing 
clay-colored stools for 2 days. Yellowish discoloration of eyes 
and skin was acute in onset and progressive in nature, which was 
associated with high-grade intermittent fever, which was relieved 
on taking antipyretics. There were no history of pain or distension 
in abdomen, vomiting, or altered bowel and bladder movements. 
There was no history of bleeding, edema, altered sensorium, 
convulsions, skin rashes, or joint pain.
The child was admitted once in private hospital for 4 days where 
he was put on IV fluids and medications. The child was given 
ursodeoxycholic acid, L-ornithine-L-aspartate, and laxatives, but 
his condition did not improve. One week after discharge, the child 
was brought to our hospital for further management.
The patient is born of the second-degree consanguineous 
marriage and there was a history of cousin sister with 
hyperbilirubinemia. There was no significant birth or neonatal 
history of any major illness. On admission, the child was 
conscious, cooperative, well oriented to time place and person. 
The child was icteric and febrile (101°F), but other vital 
parameters were normal. There were no signs of liver cell failure. 
Kayser–Fleischer ring was absent. Systemic examination showed 
hepatomegaly with liver span 13.5 cm. Liver was non-tender, 
smooth surface, firm consistency with rounded margins. Spleen 
showed mild splenomegaly, non-tender, soft consistency, well-
defined margins and notch felt 3 cm below costal margins.
Investigations showed elevated liver parameters (Table 1) with 
hepatitis A, hepatitis E, immunoglobulin M antibodies, hepatitis b virus 
surface antigen, anti-hepatitis C virus negative, and Widal test negative. 
Urine bile salts and bile pigments were present. Renal functional tests 
were normal. Ultrasonography abdomen showed hepatomegaly with 
altered echotexture suggestive of parenchymal disease, splenomegaly, 
and mild ascites. The child was further investigated for etiology. Serum 
ceruloplasmin levels were within normal limits.
Autoimmune markers were negative for serum anti-nuclear 
antibodies (ANAs), anti-smooth muscle antibodies (anti-SMAs), 
anti-mitochondrial antibodies, and liver-kidney microsomal 
antigen 1 (anti-LKM-1). Liver biopsy was done which showed 
diffuse parenchymal mononuclear, as well as portal infiltration 
(Fig. 1), lymphocytic or lymphoplasmacytic interface hepatitis 
(Fig. 2) and portal tract with dense lymphoid infiltrate, and 
only rare plasma cells (Fig. 3). Chronic hepatitis was seen 
with mild activity and portal-portal bridging (Ishak Stage 5). 
Histopathological findings were clearly suggestive of AIH.
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The child was put on prednisolone only regimen. Dose of 
prednisolone is shown in Table 2. The child was started at a dose of 
2 mg/kg/day oral prednisolone, then was tapered weekly depending 
on response clinically and biochemically to prednisolone. After 
3 days of tablet prednisolone, the child showed drastic improvement 
clinically with improved appetite, reduced icterus, and became 
afebrile. Liver function test (LFT) at day 3 and day 5 also showed 
drastic improvement (Table 1). The child was called for follow-up 
weekly and LFT was repeated during follow-up.
DISCUSSION
AIH is a rare autoimmune disorder causing chronic liver 
inflammation. It is a chronic progressive disease, characterized 
by immune-mediated destruction of the liver parenchyma and 
the presence of autoantibodies in the periphery. Wide range of 
clinical manifestations ranging from asymptomatic to fulminant 
hepatic failure is seen. Common initial symptoms include fatigue, 
muscle aches, and signs of acute liver inflammation including 
fever, jaundice, and right upper quadrant abdominal pain. Some 
individuals with AIH often have no initial symptoms and the 
disease is detected by abnormal LFTs. It is associated with other 
autoimmune diseases in one-third of the cases. The prevalence 
of AIH was 1.3% and 8.74% among all liver disease and chronic 
liver disease patients [2-4]. Although it presents at all ages, it 
is more common in adult females [5]. Majority of the cases are 
Type 1 [3-6] and are ANA or anti-SMA positive. Type 2 cases are 
anti-LKM-1 positive. Type 3 is rare and is positive for antibodies 
to soluble liver antigen (anti-SLA).
Seronegative AIH still occurs in <5% of cases [5]. Amarapurkar 
et al. in their study found that 18% were autoimmune marker 
negative [3]. Diagnosis of AIH is reached after careful exclusion 
of other more common viral, metabolic, and drug-induced liver 
diseases. Patients classically have elevated transaminases, raised 
immunoglobulin G, and positive autoantibodies [6]. It is a poorly 
defined inflammatory liver disease, without a specific diagnostic 
marker. Clinically, serologically, and histologically, it represents 
chronic relapsing hepatitis associated with plasma cell hepatic 
infiltrate, hypergammaglobulinemia, and positive autoantibodies. 
Exclusion of viral causes, drug-induced hepatitis, and metabolic 
liver disease is required to confirm the diagnosis. Histological 
features include lymphoplasmacytic interface hepatitis, lobular 
Figure 1: Low-power view with brisk diffuse parenchymal 
mononuclear infiltrate
Figure 2: Typical features with lymphoplasmacytic infiltrate with 
interface activity
Figure 3: Portal tract with dense lymphoid infiltrate with occasional 
plasma cells
Table 2: Prednisolone dosage
Dosing intervals Prednisolone (mg)
Week 1 60
Week 2 40
Week 3 20
Week 4 10
Table 1: LFTs
LFT Day 1 (before 
prednisolone)
Day 
3
Day 
5
Day 
15
Day 
21
Day 
28
AST 1125 159 90 85 77 78
ALT 1900 262.9 173.3 166.4 135 111
ALP 556 277 205.8 198 189 180
TBR 26.8 11.1 5.7 5.0 2.4 1.9
DBR 14.2 6.0 3 2.8 1.4 0.8
AST: Aspartate aminotransferase, ALT: Alanine transaminase, ALP: Alkaline phosphatase, 
TBR: Total bilirubin, DBR: Direct bilirubin, LFT: Liver function test
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hepatitis, and centrilobular necrosis [5,7,8]. Although AIH 
is uncommon, its diagnosis is important as early treatment is 
associated with significant good long-term prognosis. It is essential 
to reduce liver inflammation and improve prognosis [2,3,7]. AIH 
responds satisfactorily to immunosuppression [7].
Patients who have the features of AIH but not the autoantibodies 
are currently classified as cryptogenic chronic hepatitis [9]. These 
patients are indistinguishable from patients with type 1 AIH by 
age (mean age 42 years vs. 45 years), female predominance (67% 
vs. 79%), serum AST levels at presentation (mean serum level 
491 U/L vs. 504 U/L), serum gamma globulin concentrations 
at accession (mean serum level 2.8 g/dL vs. 3.4 g/dL), human 
leukocyte antigen (HLA) status, and histologic findings [10,11]. 
Furthermore, they respond well to corticosteroid therapy as type 1 
counterparts, entering remission (83% vs. 78%) and deteriorating 
during treatment (9% vs. 11%) [10,11].
In contrast, these patients differ from those with chronic 
viral hepatitis by having greater laboratory derangements at 
presentation, a higher frequency of multilobular necrosis on 
histologic examination, and different HLA haplotypes [10]. 
Their similarities to type 1 AIH and distinctions from chronic 
viral hepatitis justify their designation as autoantibody-negative 
AIH [11]. The previous studies have shown that 14% of patients 
with autoantibody-negative AIH have anti-SLA [12] and 33% 
have other immunoreactivities such as antibodies to liver/
pancreas [13]. These findings suggest that autoantibody-negative 
patients have AIH that has escaped detection by conventional 
immunoassays.
Alternatively, these patients might be seropositive 
for SMA or ANA (or both) but seronegative at the time 
of testing. Autoantibodies can fluctuate in titer, and such 
spontaneous fluctuations might render some patients transiently 
seronegative [14]. Novel immunoassays and serial assessments 
for conventional autoantibodies promise to secure the diagnosis 
of AIH in many of these patients [9]. Importantly, they must 
be distinguished from individuals with cryptogenic chronic 
liver disease. In the former instance, patients have an active, 
potentially aggressive, inflammatory process [10,11], whereas in 
the latter instance, patients have an inactive, frequently end-stage, 
non-descript cirrhosis [15,16].
CONCLUSION
Seronegative AIH is a rare cause of chronic liver disease in India, 
especially in children. Typical serological picture might not be 
seen in seronegative AIH. Hence, high index of suspicion is 
required to diagnose this variant of AIH as early as possible and 
start the treatment at the earliest to achieve the best outcome.
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